| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgements
|
|
|
|
33 |
S1 |
p. vii
|
artikel
|
| 2 |
Editorial Board
|
|
|
|
33 |
S1 |
p. i
|
artikel
|
| 3 |
Journal Information
|
|
|
|
33 |
S1 |
p. ii
|
artikel
|
| 4 |
27MO BDTX-1535, a CNS penetrant, irreversible inhibitor of intrinsic and acquired resistance EGFR mutations, demonstrates preclinical efficacy in NSCLC and GBM PDX models
|
Lucas, M.C.
|
|
|
33 |
S1 |
p. S14
|
artikel
|
| 5 |
5MO Comprehensive dose-finding strategy for single-agent RP-3500, a highly selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase
|
Fontana, E.
|
|
|
33 |
S1 |
p. S3-S4
|
artikel
|
| 6 |
26MO Efficacy and safety of poziotinib in treatment-naïve HER2 exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC): ZENITH20-4
|
Sun, S.
|
|
|
33 |
S1 |
p. S13
|
artikel
|
| 7 |
6MO Translational relevance of the combined treatment PARP inhibitors and AsiDNA in homologous recombination proficient tumors
|
Jdey, W.
|
|
|
33 |
S1 |
p. S4
|
artikel
|
| 8 |
7MO WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in small cell lung cancer
|
Sen, T.
|
|
|
33 |
S1 |
p. S4
|
artikel
|
| 9 |
46P AB521, a clinical-stage, potent, and selective Hypoxia-Inducible Factor (HIF)-2α inhibitor, for the treatment of renal cell carcinoma
|
Lawson, K.V.
|
|
|
33 |
S1 |
p. S21
|
artikel
|
| 10 |
22P Active immunization with a multi-peptide B cell vaccine, targeting trastuzumab and pertuzumab binding sites, prevents the formation of Her-2/neu-expressing lung metastases
|
Tobias, J.
|
|
|
33 |
S1 |
p. S11-S12
|
artikel
|
| 11 |
44P A first-in-human, open-label, dose-escalation study to investigate the safety and tolerability of CHC2014, a tropomyosin receptor kinase (TRK) inhibitor, in adult patients with advanced solid tumors
|
Yun, T.
|
|
|
33 |
S1 |
p. S20
|
artikel
|
| 12 |
45P Alofanib in subsequent therapy of advanced gastric cancer: Final results from the phase Ib clinical trial
|
Vladimirova, L.Y.
|
|
|
33 |
S1 |
p. S20
|
artikel
|
| 13 |
56P An institutional study evaluating the benefit of blood NGS over conventional hotspot molecular genetic testing in metastatic adenocarcinoma lung
|
Ashwath, R.
|
|
|
33 |
S1 |
p. S25
|
artikel
|
| 14 |
32P Anlotinib enhances the antitumor activity of high-dose irradiation combined with anti-PD-L1 by potentiating the tumor immune microenvironment in murine lung cancer
|
Yuan, M.
|
|
|
33 |
S1 |
p. S15
|
artikel
|
| 15 |
14P A novel small molecule METTL3 inhibitor exerts promising antitumor effects on oral squamous cell carcinoma
|
Arumugam, P.
|
|
|
33 |
S1 |
p. S8
|
artikel
|
| 16 |
49P Antitumor effects of cationic dendritic molecules and their complexes with microRNA in glioblastoma stem-like cells
|
Knauer, N.
|
|
|
33 |
S1 |
p. S21-S22
|
artikel
|
| 17 |
4P Antitumor efficacy of integrin αVβ3 antibody conjugated ZnO nanocarrier-based drug delivery system to target breast carcinoma
|
Vimala, K.
|
|
|
33 |
S1 |
p. S2
|
artikel
|
| 18 |
36P A point mutation replacing cysteine with arginine at position 382 (C382R) in the transmembrane domain of FGFR2 leads to response to FGF2-inhibitor pemigatinib in chemo-refractory intrahepatic cholangiocarcinoma
|
Hempel, L.C.
|
|
|
33 |
S1 |
p. S17
|
artikel
|
| 19 |
53P Assessing the reporting quality of early phase dose-finding trials
|
Yap, C.
|
|
|
33 |
S1 |
p. S24
|
artikel
|
| 20 |
42P BAL0891: A novel, small molecule, dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) with potent single agent activity
|
Lane, H.A.
|
|
|
33 |
S1 |
p. S18-S19
|
artikel
|
| 21 |
18P Baseline and dynamic changes in haemoglobin levels predict treatment response and disease progression in metastatic renal cell carcinoma
|
Yang, Y-H.
|
|
|
33 |
S1 |
p. S10
|
artikel
|
| 22 |
48P cERBB-2/HER-2neu overexpression and its prognostic significance in uterine carcinosarcoma
|
Semiz, H.S.
|
|
|
33 |
S1 |
p. S21
|
artikel
|
| 23 |
16P Checkpoint modification of BTLA-HVEM-LIGHT signaling by HSV-1 glycoprotein D (gD) improves vaccine-induced CD8+ T cell responses in pre-clinical cancer models
|
Luber, A.
|
|
|
33 |
S1 |
p. S9-S10
|
artikel
|
| 24 |
12P Circulating tumor DNA as early marker of response to treatment in stage IV gastrointestinal cancer
|
Kirchweger, P.
|
|
|
33 |
S1 |
p. S7
|
artikel
|
| 25 |
30P Comparative biochemical and cellular profiling of kinase inhibitors approved for clinical use from 2018 to 2020
|
Kooijman, J.
|
|
|
33 |
S1 |
p. S15
|
artikel
|
| 26 |
28P Discovery of potent PROTAC degraders of KRASG12C based on a reversible non-covalent KRAS binder
|
Zhang, Z.
|
|
|
33 |
S1 |
p. S14
|
artikel
|
| 27 |
17P Driving NK cell immunotherapy against NSCLC, in the context of hypoxia, using tri-specific engagers
|
Miller, J.S.
|
|
|
33 |
S1 |
p. S10
|
artikel
|
| 28 |
34P Efficacy and toxicity analysis of imatinib in newly diagnosed patients of chronic myeloid leukaemia: 18-years’ experience at a single large-volume centre
|
Yadav, R.
|
|
|
33 |
S1 |
p. S16
|
artikel
|
| 29 |
23P Engineered chemotherapy resistant γδ T-cells with combinatorial chemotherapies can enhance tumor cell immunogenicity and killing
|
Rochlin, K.M.
|
|
|
33 |
S1 |
p. S12
|
artikel
|
| 30 |
24P Evidence for synergy between TNG908, an MTAPnull-selective PRMT5 inhibitor, and sotorasib in an MTAPnull/KRASG12C xenograft model
|
Briggs, K.
|
|
|
33 |
S1 |
p. S12
|
artikel
|
| 31 |
20P Immuno-modulating effects of hyperthermia on PD-L1 and NLRC5 in ovarian cancer
|
Fezza, M.
|
|
|
33 |
S1 |
p. S11
|
artikel
|
| 32 |
25P Impact of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma (the MEMOIR study): A propensity score-matched analysis
|
Qian, D.C.
|
|
|
33 |
S1 |
p. S12
|
artikel
|
| 33 |
29P LIBRETTO-321, a phase II study of the efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancer (TC)
|
Zheng, X.
|
|
|
33 |
S1 |
p. S14
|
artikel
|
| 34 |
51P Mitochondrial pro-apoptotic properties of isolated compounds from two soft corals of Persian Gulf
|
Yegdaneh, A.
|
|
|
33 |
S1 |
p. S22
|
artikel
|
| 35 |
31P Molecular testing, treatment and outcome of patients with advanced solid tumors harboring a NTRK1, NTRK2 or NTRK3 gene fusion: Study design and first results of the REALTRK registry
|
Vannier, C.
|
|
|
33 |
S1 |
p. S15
|
artikel
|
| 36 |
43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy
|
Leal, T.A.
|
|
|
33 |
S1 |
p. S19-S20
|
artikel
|
| 37 |
38P New tetraamine compounds targeting BCSCs from chemoresistant basal-like TNBC subtypes
|
Sevillano Chapartegui, A.
|
|
|
33 |
S1 |
p. S17
|
artikel
|
| 38 |
11P Novel HDAC6 inhibitors show anti-lymphoma activity alone and in combination with venetoclax and copanlisib
|
Mensah, A.A.
|
|
|
33 |
S1 |
p. S7
|
artikel
|
| 39 |
52P Novel inhibitors of androgen receptor with antiproliferative potency against hormone-sensitive and hormone-resistant breast cancer cells
|
Scherbakov, A.M.
|
|
|
33 |
S1 |
p. S22-S23
|
artikel
|
| 40 |
35P NSCLC: Real-world data analysis from a chain of oncology centres in Western India
|
Shivchhand, A.A.
|
|
|
33 |
S1 |
p. S16
|
artikel
|
| 41 |
39P OLIMPIA dataset: Radiomics to predict outcomes in EGFR-mutant non-small cell lung cancer
|
Pérez, G.
|
|
|
33 |
S1 |
p. S18
|
artikel
|
| 42 |
8P Pharmacokinetic (PK) profile and food effect of RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase in patients (pts) with cancer
|
Lheureux, S.
|
|
|
33 |
S1 |
p. S4-S5
|
artikel
|
| 43 |
55P Potential benefits of extensive genomic analysis in patients with KRAS mutated solid tumors: Concurrent alterations and potential targets
|
Jacobsen, I.C.
|
|
|
33 |
S1 |
p. S25
|
artikel
|
| 44 |
9P Preliminary population pharmacokinetic (popPK) co-variates and exposure response (ER) assessment of QT for RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase
|
Lee, E.
|
|
|
33 |
S1 |
p. S5-S6
|
artikel
|
| 45 |
47P Prevalence of mutations in common tumour types in Northern England and utility of Experimental Cancer Medicine Centre (ECMC) CRUK Trial Finder
|
Rae, S.C.A.
|
|
|
33 |
S1 |
p. S21
|
artikel
|
| 46 |
40P Real-world clinical genomic analysis of patients with BRAF mutated cancers identifies BRAF class II and III as a population of unmet medical need
|
Severson, P.
|
|
|
33 |
S1 |
p. S18
|
artikel
|
| 47 |
37P Retrospective analysis of real-world data to evaluate actionability of a large molecular profiling panel in solid tumors (REALM study)
|
Leroy, K.
|
|
|
33 |
S1 |
p. S17
|
artikel
|
| 48 |
1P Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic non-small cell lung cancer (NSCLC)
|
Gao, B.
|
|
|
33 |
S1 |
p. S1
|
artikel
|
| 49 |
2P Sitravatinib + tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC)
|
Zhou, Q.
|
|
|
33 |
S1 |
p. S1-S2
|
artikel
|
| 50 |
10P SKLB-0322, a novel EZH2 covalent inhibitor, exerts potent anti-tumor activity in ovarian cancer
|
Zhu, Y.
|
|
|
33 |
S1 |
p. S7
|
artikel
|
| 51 |
15P STELLAR-001: A phase I study of the anti-C5aR avdoralimab in combination with the anti-PD-L1 durvalumab in advanced solid tumors
|
Bennouna, J.
|
|
|
33 |
S1 |
p. S9
|
artikel
|
| 52 |
33P Synergistic effects of alpelisib (PI3K inhibitor) and ribociclib (CDK 4/6 inhibitor) in preclinical colorectal cancer (CRC) models
|
Aslam, R.
|
|
|
33 |
S1 |
p. S16
|
artikel
|
| 53 |
54P Targeted treatment options for childhood hepatoblastoma using high-throughput drug screening
|
Nousiainen, R.
|
|
|
33 |
S1 |
p. S24
|
artikel
|
| 54 |
3P Targeting pancreatic adenocarcinoma upregulated factor (PAUF) to treat pancreatic cancer (PC): In vivo efficacy and safety of PBP1510, a first in class monoclonal antibody (mAb)
|
Pradhan, S.
|
|
|
33 |
S1 |
p. S2
|
artikel
|
| 55 |
50P Targeting the renin-angiotensin system in gastric cancer therapeutics
|
Chimed, S.
|
|
|
33 |
S1 |
p. S22
|
artikel
|
| 56 |
41P The SARS-CoV-2 vaccine and enrollment of patients with cancer in phase I trials: The experience at Institute Gustave Roussy
|
Belcaid, L.
|
|
|
33 |
S1 |
p. S18
|
artikel
|
| 57 |
13P Transcriptional profiling of FET-rearranged sarcomas in response to SP-2577
|
Rask, G.
|
|
|
33 |
S1 |
p. S7-S8
|
artikel
|
| 58 |
21P Transcriptomic mapping of integrins and immune activation in high-grade serous ovarian cancer
|
Rojas Laimito, K.I.
|
|
|
33 |
S1 |
p. S11
|
artikel
|
| 59 |
19P Tumor retargeting universal chimeric antigen receptor T cell (TRUE-CAR T) therapy in solid tumors
|
Meng, F.
|
|
|
33 |
S1 |
p. S10-S11
|
artikel
|
| 60 |
Society Pages
|
|
|
|
33 |
S1 |
p. v-vi
|
artikel
|
| 61 |
Table of Contents
|
|
|
|
33 |
S1 |
p. iv
|
artikel
|
| 62 |
Title Page
|
|
|
|
33 |
S1 |
p. iii
|
artikel
|
Tijdschrift beschrijving